We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$63.3M
Cap. Flow %
3.6%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.35%
3 Consumer Staples 0.26%
4 Consumer Discretionary 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCRX
76
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.82M 0.16%
+2,150,000
New +$2.74M
MGCD
77
DELISTED
MGC Diagnostics Corporation
MGCD
$2.52M 0.14%
302,327
-27,406
-8% -$242K
AERI
78
DELISTED
Aerie Pharmaceuticals
AERI
$2.27M 0.13%
50,000
– –
PTLA
79
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.27M 0.13%
+57,870
New +$1.84M
ADYX
80
DELISTED
Adynxx Inc
ADYX
$2.14M 0.12%
70,566
+38,533
+120% +$1.37M
UNH icon
81
UnitedHealth
UNH
$337B
$2.13M 0.12%
13,000
+9,777
+303% +$1.6M
RARX
82
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.13M 0.12%
100,000
-65,000
-39% -$1.24M
RNAC icon
83
Cartesian Therapeutics
RNAC
$239M
$2.03M 0.12%
4,729
– –
SAGE
84
CALL
DELISTED
Sage Therapeutics
SAGE
$1.97M 0.11%
+200,000
New +$11.7M
IMMU
85
DELISTED
Immunomedics Inc
IMMU
$1.94M 0.11%
+300,060
New +$1.52M
EIGR
86
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.8M 0.1%
5,256
– –
AFMD
87
DELISTED
Affimed
AFMD
$1.69M 0.1%
73,430
– –
ARWR icon
88
Arrowhead Research
ARWR
$9.98B
$1.57M 0.09%
847,458
– –
SIOX
89
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.42M 0.08%
+25,000
New +$2.62M
CRIS icon
90
Curis
CRIS
$2.74M
$1.39M 0.08%
+250
New +$1.39M
CSBR icon
91
Champions Oncology
CSBR
$66.4M
$1.16M 0.07%
366,972
-5,625
-2% -$19.7K
BLCM
92
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.06M 0.06%
+8,620
New +$1.13M
EXEL icon
93
Exelixis
EXEL
$14.1B
$1M 0.06%
46,361
– –
AKRX
94
DELISTED
Akorn Inc
AKRX
$963K 0.05%
+40,000
New +$871K
ZSAN
95
DELISTED
Zosano Pharma Corporation
ZSAN
$950K 0.05%
+714
New +$862K
GRDX
96
GridAI Technologies Corp
GRDX
$21.5M
$877K 0.05%
2
– –
INCY icon
97
Incyte
INCY
$24.7B
$751K 0.04%
5,619
– –
WCG
98
DELISTED
Wellcare Health Plans, Inc.
WCG
$741K 0.04%
5,283
+227
+4% +$32.3K
STLA icon
99
Stellantis
STLA
$14.8B
$678K 0.04%
62,248
– –
LNTH icon
100
Lantheus
LNTH
$6.58B
$672K 0.04%
53,763
– –
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $63.3M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.